Ibrutinib (CAS 936563-96-1)

Application and positioning

Ibrutinib is an irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell receptor signalling. It is used in oral capsules and tablets for chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenström macroglobulinaemia and chronic graft-versus-host disease. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Lenvatinib Mesylate (CAS 857890-39-2)
• Lorlatinib (CAS 1454846-35-5)
• Neratinib Maleate (CAS 915942-22-2)
• Nintedanib Ethanesulfonate (CAS 656247-18-6)
• 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (CAS 330786-24-8)
• (S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate (CAS 1420478-88-1)
• 4-Phenoxyphenylboronic acid (CAS 51067-38-0)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.